Grifols SA

Grifols is a pharmaceutical manufacturer based in Barcelona, Spain, that specializes in plasma-derived medicines and diagnostic solutions. The company develops and produces hemoderivatives—therapeutic proteins extracted from human plasma—used to treat conditions across immunology, infectious disease, hepatology, intensive care, pulmonology, hematology, and neurology. Its product portfolio includes immunoglobulins, albumin, thrombin, and other plasma-derived proteins marketed globally to hospitals, clinics, and patients.

The company operates through four primary segments. The Biopharma segment supplies plasma-derived medicines for therapeutic use. The Diagnostic segment manufactures and sells testing equipment, reagents, and provides transfusion medicine and clinical diagnostic services. The Bio Supplies segment produces biological products including albumin and intermediate plasma components for use by pharmaceutical and biotech companies, as well as whole blood and processed plasma for diagnostic and research applications. A fourth segment encompasses hospital solutions, including intravenous fluids, clinical nutrition products, medical devices for interventional procedures, and hospital automation technology, alongside contract manufacturing and engineering services.

Grifols operates at significant scale with approximately 25,258 full-time employees and maintains a global presence across North America, Europe, and international markets. The company was founded in 1909 and is listed on Nasdaq.